News
HistoSonics Announces Published Results of Phase I Liver Tumor Trial
HistoSonics announced today the publication of results from their prospective Phase I clinical tr...
News
HistoSonics Receives FDA “Breakthrough Device Designation” for Novel Sonic Beam Therapy
HistoSonics announced today that the U.S. Food and Drug Administration (FDA) has granted the comp...
News
HistoSonics Announces Milestone As AMA Issues Unique Category III CPT® Code For Histotripsy Of Liver
HistoSonics is pleased to announce that the American Medical Association (AMA) has issued a new C...
#HOPE4LIVER
HistoSonics Announces First Patient Treated in European Clinical Trial
HistoSonics announced today that the first patient has been treated as part of the company's #HOP...
#HOPE4LIVER
HistoSonics Announces First Patient Treated in US Clinical Study of Novel Sonic Beam Therapy for Liver Tumors
HistoSonics announced today the treatment of the first patient in the #HOPE4LIVER US Study. The ...
#HOPE4LIVER
HistoSonics Receives Approval To Begin European #HOPE4LIVER Clinical Study
HistoSonics announced today that it has received approval to initiate the company’s second Europe...
News
HistoSonics Announces $15M Debt Facility Agreement with Signature Bank
HistoSonics Announces $15M Debt Facility Agreement with Signature Bank. HistoSonics is proud to ...
News
HistoSonics Selected as 2020 Red Herring Top 100 North America Winner
HistoSonics was chosen as a 2020 Red Herring Top 100 North America Winner. “What has excited me m...
#HOPE4LIVER
HistoSonics Announces Approval of its #HOPE4LIVER US Clinical Study
HistoSonics announced today that it has received approval of an Investigational Device Exemption ...
News
HistoSonics Announces $40 Million Financing
HistoSonics announced today that it has closed $40 million in an oversubscribed Series C-1 financ...